- Full Year 2023 Basilea Pharmaceutica AG Allschwil Earnings Call TranscriptFeb 13, 2024CHF36.5 (+8.79%)Earnings
- Basilea Pharmaceutica AG Allschwil to Acquire the Rights to Fosmanogepix from Amplyx Pharmaceuticals Inc Call TranscriptNov 13, 2023
- Half Year 2023 Basilea Pharmaceutica AG Allschwil Earnings Call TranscriptAug 15, 2023CHF47.35 (+11.67%)Earnings
- Full Year 2022 Basilea Pharmaceutica AG Earnings Call TranscriptFeb 14, 2023CHF49.55 (+3.55%)Earnings
- Half Year 2022 Basilea Pharmaceutica AG Earnings Call TranscriptAug 16, 2022CHF40.25 (-7.47%)Earnings
- Basilea Pharmaceutica AG to Discuss the ERADICATE Topline Results Call TranscriptJun 28, 2022
- Basilea Pharmaceutica AG at UBS Global Healthcare Conference TranscriptMay 24, 2022
- Full Year 2021 Basilea Pharmaceutica AG Earnings Call TranscriptFeb 15, 2022CHF41.72 (+4.04%)Earnings
- Half Year 2021 Basilea Pharmaceutica AG Earnings Call TranscriptAug 17, 2021CHF45.16 (-1.61%)Earnings
- Full Year 2020 Basilea Pharmaceutica AG Earnings Call TranscriptFeb 16, 2021CHF58.8 (-3.61%)Earnings
- Half Year 2020 Basilea Pharmaceutica AG Earnings Call TranscriptAug 11, 2020CHF49 (+4.66%)Earnings
- Basilea Pharmaceutica AG at UBS Global Healthcare Conference (Virtual) TranscriptMay 19, 2020
- Full Year 2019 Basilea Pharmaceutica AG Earnings Call TranscriptFeb 18, 2020CHF56.35 (-5.77%)Earnings
- Half Year 2019 Basilea Pharmaceutica AG Earnings Call TranscriptAug 20, 2019CHF39.16 (+5.90%)Earnings
- Basilea Pharmaceutica AG at UBS Global Healthcare Conference TranscriptMay 21, 2019
Basilea Pharmaceutica AG at UBS Global Healthcare Conference Transcript
Good afternoon. Thank you for coming to 2019 UBS Health Care Conference. The next presenter will be David Veitch from Basilea Pharmaceutica. He's the CEO, and please welcome David.
Thank you very much and good afternoon to everyone. I will try in the next 25 minutes just to give you an overview of the company, our priorities and what the immediate future lies in store for Basilea Pharmaceutica.
Just at a glance, the key high-level summary. We were set up originally as an anti-infective, antibiotic developer when we were spun out from Roche in 2000. We went public in 2004 in the Swiss SIX Stock Exchange. And during the course of the last 19 years, we have brought 3 products to market, all the way from research to market. 2 of these we have still in our portfolio today, that's an invasive fungal infection product and an antibiotic. And then we had another other agent called Toctino, which was a hand eczema product which we actually sold in 2012 to GSK Stiefel. So that no longer is in our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)